While not a mind-blowing move, it is good to see that the Exact Sciences Corporation ( NASDAQ:EXAS ) share price…
An updated version of Exact Sciences key product just got regulatory approval. That could help the healthcare stock stage a…
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high…
…
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.…
…
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard…
Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as…
…
Exact Sciences (EXAS) progress with strategic priority and strong solvency bode well.…
EXAS earnings call for the period ending June 30, 2024.…
Exact Sciences (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.…
…
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.…
Exact Sciences (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening…
MADISON, Wisconsin--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), ein führender Anbieter von Krebsfrüherkennungs- und Diagnosetests, wird auf der Jahrestagung der American…
Exact Sciences stock drops as Guardant Health test supported by FDA panel…
EXAS earnings call for the period ending March 31, 2024.…
Exact Sciences Shares Drop 10% on Earnings Miss…
Exact Sciences (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth,…
…
A decade ago, Exact Sciences launched Cologuard, impacting the fight against colorectal cancer. Its growth of 7000% is in part…
Exact Sciences EVP sells $140k in company stock…
Citi sees Exact Sciences shares climbing after rivals data disappoints…
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.…
…
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.…
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.…
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
EXAS earnings call for the period ending December 31, 2023.…
Robust revenues from Exact Sciences (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.…
Exact Sciences (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer…
Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the…
…
Exact Sciences projects 17% Q4 revenue growth…
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.…
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…
Both of these biotech stocks have been market-beaters over the prior 10 years. One stock, however, is a better buy…
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.…
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.…
…
EXAS earnings call for the period ending September 30, 2023.…
…
Exact Sciences (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.…
Genetics is the study of genes, their variations and hereditary characteristics, as well as how these traits are passed on…
• Fast jeder Titel in ARKs Flaggschiffstrategie soll im Bereich der künstlichen Intelligenz engagiert sein• Wood setzt auf Unternehmen mit…
Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.…
…
The business is unprofitable, but it has been growing at an impressive rate in recent years....…
Baranick, Brian - Vorstand - Tag der Transaktion: 2023-08-07...…